¼¼°èÀÇ ÆÐÇ÷Áõ Áø´Ü ½ÃÀå
Sepsis Diagnostics
»óǰÄÚµå : 1563854
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 173 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀº 2030³â±îÁö 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³â¿¡ 6¾ï 9,630¸¸ ´Þ·¯·Î ÃßÁ¤µÈ ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.5%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¹Ì»ý¹°ÇÐ ±â¼úÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.0%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã¿¡´Â 7¾ï 4,980¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸é¿ªºÐ¼®±â¼ú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 1¾ï 8,400¸¸ ´Þ·¯, Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀº 2023³â 1¾ï 8,400¸¸ ´Þ·¯·Î ÃßÁ¤µÆ½À´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» 12.7%·Î 2030³â±îÁö 2¾ï 9,940¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 3.0%¿Í 7.4%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÆÐÇ÷Áõ Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à

÷´ÜÀûÀÎ ÆÐÇ÷Áõ Áø´Ü ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ´Â ÀÌÀ¯¶õ?

ÆÐÇ÷ÁõÀº °¨¿°¿¡ ´ëÇÑ ½ÅüÀÇ ±Ø´ÜÀûÀÎ ¹ÝÀÀÀ¸·Î ÀÎÇÑ »ý¸íÀ» À§ÇùÇÏ´Â º´ÅÂÀ̸ç, ¿©ÀüÈ÷ ¼¼°èÀÇ »ç¸Á ¿øÀÎÀÇ »óÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í °Ç°­ °ü¸® ºñ¿ëÀ» ÁÙÀ̱â À§Çؼ­´Â Á¶±â ¹ß°ß°ú Àû½Ã °³ÀÔÀÌ ÇʼöÀûÀ̱⠶§¹®¿¡ ÷´Ü ÆÐÇ÷Áõ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ±Þ¼ÓÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀÎ Áø´Ü ¹æ¹ýÀº ½Ã°£ Áö¿¬, Á¤È®¼º ¹× ÆÐÇ÷ÁõÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â º¹À⼺°ú °°Àº ¹®Á¦¿¡ Á÷¸éÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ¿¡ ¹ÝÇØ º´¿ø°ú ÀÓ»ó½Ç¿¡¼­´Â ÆÐÇ÷ÁõÀÇ Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϱâ À§ÇØ ºÐÀÚÁø´Ü, ½Å¼ÓÇ׿ø°Ë»ç, ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ºÐ¼® µî Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÁýÁßÄ¡·á½Ç(ICU)°ú ±¸±ÞºÎ¹®¿¡¼­ ÆÐÇ÷ÁõÀÇ À¯º´·üÀÌ ³ô¾ÆÁ® ÀÌ·¯ÇÑ Áøº¸ÀûÀÎ Áø´Ü µµ±¸ÀÇ ¼¼°èÀÇ º¸±ÞÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ Áøº¸´Â ÆÐÇ÷Áõ Áø´Ü¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

±â¼úÀÇ Áøº¸´Â ÆÐÇ÷Áõ Áø´Ü ¾à¹°ÀÇ »óȲÀ» ÇöÀúÇÏ°Ô Çâ»ó½ÃŰ°í ´õ ³ôÀº Á¤È®µµ, ¼Óµµ ¹× ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)°ú Â÷¼¼´ë ½ÃÄö½Ì(NGS)À» Æ÷ÇÔÇÑ ºÐÀÚÁø´ÜÀÇ Çõ½ÅÀº º´¿øÃ¼¿Í Ç×»ýÁ¦ ³»¼º ÇÁ·ÎÆÄÀÏÀÇ ½Å¼ÓÇÑ È®ÀÎÀ» °¡´ÉÇÏ°Ô Çϰí Ç¥Àû Ä¡·á¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿È­ Ç÷§Æû°ú POC(Point of Care) ÀåºñÀÇ °³¹ß·Î Áø´Ü ´É·ÂÀÌ Ä§´ë ¿·¿¡ °¡±î¿öÁö°í °á°ú°¡ ³ª¿Ã ¶§±îÁöÀÇ ½Ã°£ÀÌ ´ÜÃàµÇ°í ÀÓ»óÀû ÀÇ»ç°áÁ¤ÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. AI ¹× ¸Ó½Å·¯´× ¾Ë°í¸®Áòµµ Áø´Ü µµ±¸¿¡ ÅëÇÕµÇ¾î º¹ÀâÇÑ µ¥ÀÌÅÍ ¼¼Æ®¸¦ ºÐ¼®ÇÏ°í ÆÐÇ÷Áõ °á°ú¸¦ º¸´Ù Á¤È®ÇÏ°Ô ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÁ·ÎÄ®½ÃÅä´Ñ(PCT), CRP, ¶ôÆ®»ê ¼öÄ¡ µîÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÑ °Ë»çÀÇ ½ÃÀÛÀº ÀÓ»ó°¡¿¡°Ô ÆÐÇ÷ÁõÀÇ ÁßÁõµµ¿Í ÁøÇà¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÏ¿© Áøº¸µÈ Áø´Ü ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ÆÐÇ÷Áõ Áø´ÜÀÇ Ã¤¿ëÀ» ¼±µµÇÏ´Â ½ÃÀå ¼¼ºÐÈ­´Â?

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀº ±â¼ú, Á¦Ç° À¯Çü, º´¿øÃ¼, °Ë»ç À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù. ÁÖ¿ä ±â¼ú·Î´Â ºÐÀÚÁø´Ü, ¸é¿ª ÃøÁ¤, ¹Ì»ý¹°ÇÐ, À¯µ¿ ¼¼Æ÷ °èÃø¹ý µîÀÌ ÀÖÀ¸¸ç, ±× Áß¿¡¼­µµ ºÐÀÚÁø´ÜÀº ½Å¼ÓÇϰí Á¤È®ÇÑ º´¿øÃ¼ È®ÀÎÀÌ °¡´ÉÇϱ⠶§¹®¿¡ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. Á¦Ç° À¯ÇüÀº Àåºñ, ½Ã¾àºÎÅÍ ¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º¿¡ À̸£±â±îÁö ´Ù¾çÇÏÁö¸¸, ½Ã¾à ¹× ¼Ò¸ðǰÀº Á¤±âÀûÀÎ ¼ö¿ä·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ÆÐÇ÷Áõ Áø´ÜÀÇ ´ë»óÀÌ µÇ´Â º´¿øÃ¼¿¡´Â ¼¼±Õ¼º º´¿øÃ¼, Áø±Õ¼º º´¿øÃ¼, ¹ÙÀÌ·¯½º¼º º´¿øÃ¼°¡ Æ÷ÇԵǸç, ÀÓ»ó ÇöÀå¿¡¼­ ¼¼±Õ °¨¿°ÀÇ ¹ß»ý·üÀÌ ³ô±â ¶§¹®¿¡ ¼¼±Õ¼º º´¿øÃ¼°¡ °¡Àå ÈçÇÕ´Ï´Ù. ÆÐÇ÷Áõ Áø´ÜÀÇ ÃÖÁ¾ »ç¿ëÀÚ´Â º´¿ø, º´¸® °Ë»ç½Ç, ¿¬±¸ ±â°üÀ» Æ÷ÇÔÇϸç, ICU ¹× ÀÀ±Þ½Ç¿¡¼­ ÆÐÇ÷Áõ »ç·Ê°¡ ¸¹±â ¶§¹®¿¡ º´¿øÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì¿Í À¯·´ÀÌ Ã·´ÜÀûÀÎ ÇコÄɾî ÀÎÇÁ¶ó¿Í ³ôÀº ÀÎÁöµµ·Î ÁÖ¿ä ½ÃÀåÀÌ µÇ°í ÀÖ´Â ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áÅõÀÚ Áõ°¡¿Í ÆÐÇ÷Áõ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °í¼ºÀåÁö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº?

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ÆÐÇ÷ÁõÀÇ À¯º´·ü Áõ°¡, ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü µµ±¸ÀÇ Çʿ伺, ºÐÀÚ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â Áø´ÜÀÇ Áøº¸ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. ´Ü½Ã°£¿¡ ³ôÀº °¨µµ¸¦ Á¦°øÇÏ´Â Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ±â±â¿Í ÀÚµ¿È­ Ç÷§Æû ½ÃÀå °³Ã´ÀÌ º´¿øÀ̳ª Áø´Ü ½ÇÇè½Ç¿¡¼­ ½ÃÀå µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× Ç¥Àû ¿ä¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡´Â Á¤È®ÇÑ º´¿øÃ¼ È®ÀÎ ¹× Ç×»ýÁ¦ °¨¼ö¼º °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â °í±Þ ÆÐÇ÷Áõ Áø´ÜÀÇ »ç¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÆÐÇ÷ÁõÀ¸·Î ÀÎÇÑ »ç¸Á·ü °¨¼Ò¿Í Á¶±â ¹ß°ß °³¼±À» ¸ñÇ¥·Î ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í °Ç°­ °ü¸® ÇÁ·Î±×·¥ Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å±Ô ÆÐÇ÷Áõ ¹ÙÀÌ¿À¸¶Ä¿, ÀΰøÁö´É ±â¹Ý Áø´Ü µµ±¸, ½Å¼ÓÇÑ ¸ÖƼÇ÷º½º ºÐ¼®¿¡ ´ëÇÑ R&D ÅõÀÚ Áõ°¡°¡ ½ÃÀå È®´ë¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ Àü 46»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sepsis Diagnostics Market to Reach US$1.2 Billion by 2030

The global market for Sepsis Diagnostics estimated at US$696.3 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Microbiology Technology, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$749.8 Million by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$184.0 Million While China is Forecast to Grow at 12.7% CAGR

The Sepsis Diagnostics market in the U.S. is estimated at US$184.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$299.4 Million by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Sepsis Diagnostics Market - Key Trends and Drivers Summarized

Why Is the Demand for Advanced Sepsis Diagnostics Growing Rapidly?

Sepsis, a life-threatening condition resulting from the body’s extreme response to infection, remains a leading cause of mortality worldwide. The demand for advanced sepsis diagnostics is rapidly increasing due to the need for early detection and timely intervention, which are critical for improving patient outcomes and reducing healthcare costs. Traditional diagnostic methods often face challenges related to time delays, accuracy, and the complexity of identifying sepsis at an early stage. In response, hospitals and clinical laboratories are increasingly adopting innovative diagnostic solutions, such as molecular diagnostics, rapid antigen tests, and biomarker-based assays, to enable precise and swift diagnosis of sepsis. The high prevalence of sepsis, particularly in intensive care units (ICUs) and emergency departments, is further driving the adoption of these advanced diagnostic tools globally.

How Are Technological Advancements Impacting Sepsis Diagnostics?

Technological advancements are significantly enhancing the sepsis diagnostics landscape, offering greater accuracy, speed, and reliability. Innovations in molecular diagnostics, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are enabling rapid identification of pathogens and their antibiotic resistance profiles, facilitating targeted therapy. Additionally, the development of automated platforms and point-of-care (POC) devices is bringing diagnostic capabilities closer to the bedside, reducing the time-to-results and improving clinical decision-making. AI and machine learning algorithms are also being integrated into diagnostic tools to analyze complex datasets and predict sepsis outcomes more accurately. Furthermore, the rise of biomarker-based tests, such as procalcitonin (PCT), C-reactive protein (CRP), and lactate levels, is providing clinicians with critical information on the severity and progression of sepsis, driving the market for advanced diagnostics.

Which Market Segments Are Leading the Adoption of Sepsis Diagnostics?

The sepsis diagnostics market is segmented by technology, product type, pathogen, testing type, end-user, and region. Key technologies include molecular diagnostics, immunoassays, microbiology, and flow cytometry, with molecular diagnostics leading due to their rapid and precise pathogen identification capabilities. Product types range from instruments and reagents to software and services, with reagents and consumables accounting for the largest share owing to their recurring demand. Pathogens covered in sepsis diagnostics include bacterial, fungal, and viral pathogens, with bacterial sepsis diagnostics being the most common due to the high incidence of bacterial infections in clinical settings. End-users of sepsis diagnostics include hospitals, pathology labs, and research institutes, with hospitals dominating the market due to the high volume of sepsis cases in ICUs and emergency departments. Geographically, North America and Europe are the leading markets due to advanced healthcare infrastructure and high awareness, while Asia-Pacific is emerging as a high-growth region driven by increasing healthcare investments and rising sepsis awareness.

What Are the Key Drivers of Growth in the Sepsis Diagnostics Market?

The growth in the sepsis diagnostics market is driven by several factors, including the increasing prevalence of sepsis, the need for rapid and accurate diagnostic tools, and advancements in molecular and biomarker-based diagnostics. The development of point-of-care devices and automated platforms that provide quick turnaround times and high sensitivity is driving market adoption across hospitals and diagnostic labs. The growing focus on personalized medicine and targeted therapies is expanding the use of advanced sepsis diagnostics that enable precise pathogen identification and antibiotic susceptibility testing. The rise of government initiatives and healthcare programs aimed at reducing sepsis mortality rates and improving early detection is creating new opportunities for market growth. Additionally, the increasing investments in R&D for novel sepsis biomarkers, AI-based diagnostic tools, and rapid multiplex assays are further supporting market expansion.

Select Competitors (Total 46 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â